Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-11-17
DOI
10.1007/s00262-020-02699-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Simultaneous development of Graves’ disease and type 1 diabetes during anti‐programmed cell death‐1 therapy: A case report
- (2020) Susumu Kurihara et al. Journal of Diabetes Investigation
- A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
- (2019) Jeroen de Filette et al. HORMONE AND METABOLIC RESEARCH
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
- (2019) Yucai Wang et al. JAMA Oncology
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer
- (2019) Fiamma Berner et al. JAMA Oncology
- Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature
- (2019) Ashray Gunjur et al. Journal for ImmunoTherapy of Cancer
- Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
- (2019) Jianchun Duan et al. JAMA Oncology
- Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
- (2019) Puyuan Xing et al. Journal for ImmunoTherapy of Cancer
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
- (2018) Fabio Conforti et al. LANCET ONCOLOGY
- Autoimmune Polyendocrine Syndromes
- (2018) Eystein S. Husebye et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy-induced autoimmune diabetes and concomitant hypophysitis
- (2018) Melissa Sum et al. Pituitary
- Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab
- (2018) Kanako Sakurai et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Endocrine toxicity of cancer immunotherapy targeting immune checkpoints
- (2018) Lee-Shing Chang et al. ENDOCRINE REVIEWS
- Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors
- (2018) Karthik Suresh et al. Journal of Thoracic Oncology
- Rheumatic immune-related adverse events from cancer immunotherapy
- (2018) Leonard H. Calabrese et al. Nature Reviews Rheumatology
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
- (2018) Cheng Xu et al. BMJ-British Medical Journal
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response
- (2017) Lucien Marchand et al. Journal of Thoracic Oncology
- Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
- (2017) Hye In Kim et al. OncoImmunology
- Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes
- (2016) Sung Hye Kong et al. ACTA DIABETOLOGICA
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome
- (2016) Elizabeth Hansen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment
- (2016) Malik Asif Humayun et al. Hormones-International Journal of Endocrinology and Metabolism
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
- (2016) Jared R. Lowe et al. Journal for ImmunoTherapy of Cancer
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
- (2014) Paolo A Ascierto et al. Journal of Translational Medicine
- Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
- (2014) Desirée Schubert et al. NATURE MEDICINE
- HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk: Analysis of the Type 1 Diabetes Genetics Consortium Families
- (2008) H. Erlich et al. DIABETES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now